Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Revision total elbow arthroplasty failure rates: the impact of primary arthroplasty failure etiology on subsequent revisions.

DeBernardis DA, Horneff JG, Davis DE, Ramsey ML, Pontes MC, Austin LS.

J Shoulder Elbow Surg. 2020 Feb;29(2):321-328. doi: 10.1016/j.jse.2019.10.010. Epub 2019 Dec 13.

PMID:
31843239
2.
3.

Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.

Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P, Barni S, Turci D, Drudi G, Lonardi S, Gallo L, Maley F, Monfardini S.

Ann Oncol. 2002 Dec;13(12):1882-92.

5.

Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination.

Cascinu S, Catalano V, Aschele C, Barni S, Debernardis D, Gallo L, Bandelloni R, Staccioli MP, Baldelli AM, Brenna A, Valenti A, Muretto P, Catalano G.

Ann Oncol. 2000 Aug;11(8):1053-6.

6.

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.

Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A.

J Clin Oncol. 1999 Jun;17(6):1760-70.

PMID:
10561213
7.

Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.

Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P, Catalano G.

Clin Cancer Res. 1999 Aug;5(8):1996-9.

8.

Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.

Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR.

Clin Cancer Res. 1998 May;4(5):1323-30.

9.

p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.

Debernardis D, Siré EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M.

Cancer Res. 1997 Mar 1;57(5):870-4.

10.

DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.

De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Siré E, Arzani D, Stanzione S, Parodi S, D'Incalci M, Russo P, Broggini M.

Br J Cancer. 1997;76(4):474-9.

11.

Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines.

Debernardis D, Stanzione S, Ottoboni C, Clerico L, Mancuso T, Parodi S, Russo P.

J Pharmacol Exp Ther. 1996 Oct;279(1):84-90.

PMID:
8858979
12.

Interactions between taxol and camptothecin.

Debernardis D, Cimoli G, Parodi S, Russo P.

Anticancer Drugs. 1996 Jul;7(5):531-4.

PMID:
8862720
13.

NADPH diaphorase activity around the suprachiasmatic nucleus in rat brain.

Lupi D, Debernardis D, Vallerga S, Morgan PJ, Djamgoz MB.

Cell Tissue Res. 1996 Feb;283(2):335-8.

PMID:
8593663
14.

In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.

Guglielmi A, Aschele C, Mori A, Baldo C, Russo P, Debernardis D, Valenti M, Bruno S, Taverna M, Rosso R, et al.

Clin Cancer Res. 1995 Nov;1(11):1337-44.

15.

Interferon-alpha or beta potentiate platinum analogous in human glioblastoma cell lines.

Stanzione S, Cimoli G, Debernardis D, Michelotti A, Conte P, Parodi S, Russo P.

Mutat Res. 1995 Nov;348(3):131-5.

PMID:
8524365
16.

Tumor-necrosis-factor and DNA topoisomerase-ii inhibitors in human ovarian-cancer - potential role in chemotherapy.

Aluigi M, Debernardis D, Cimoli G, Ottoboni C, Parodi S, Russo P.

Int J Oncol. 1995 Sep;7(3):461-7.

PMID:
21552860

Supplemental Content

Loading ...
Support Center